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Abstract
Background: MHC-II restricted CD4+ T cells are dependent on antigen presenting cells (APC) for their activation. APC
dysfunction in HIV-infected individuals could accelerate or exacerbate CD4+ T cell dysfunction and may contribute to
increased levels of immunodeficiency seen in some patients regardless of their CD4+ T cell numbers. Here we test the
hypothesis that APC from HIV-infected individuals have diminished antigen processing and presentation capacity.
Methodology/Principal Findings: Monocytes (MN) were purified by immuno-magnetic bead isolation techniques from
HLA-DR1.01+ or DR15.01+ HIV-infected and uninfected individuals. MN were analyzed for surface MHC-II expression and for
antigen processing and presentation capacity after overnight incubation with soluble antigen or peptide and HLA-DR
matched T cell hybridomas. Surface expression of HLA-DR was 20% reduced (p,0.03) on MN from HIV-infected individuals.
In spite of this, there was no significant difference in antigen processing and presentation by MN from 14 HIV-infected
donors (8 HLA-DR1.01+ and 6 HLA-DR15.01+) compared to 24 HIV-uninfected HLA-matched subjects.
Conclusions/Significance: We demonstrated that MHC class II antigen processing and presentation is preserved in MN from
HIV-infected individuals. This further supports the concept that this aspect of APC function does not further contribute to
CD4+ T cell dysfunction in HIV disease.
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Introduction
Activation of CD4+ T cells is dependent on presentation of
antigen by MHC-II molecules on APC. Although loss of CD4+ T
cells is responsible for the profound T-cell immunodeficiency of
AIDS, APC dysfunction in HIV+ individuals could accelerate or
exacerbate CD4+ T-cell dysfunction.
Few studies have analyzed the function of APC from HIV-
infected and uninfected individuals using antigen-specific T cell
responses. In vitro infection of MN with very high concentrations of
HIV produced significant defects in antigen processing [1,2]. It is
difficult to extrapolate these in vitro data to the in vivo setting in
HIV-infected subjects since the frequency of HIV-infection in
macrophages from HIV+ patients was only 1/2,300 to 1/37,000
cells [3,4]. Two studies from Blauvelt et al. measured antigen
presentation in HIV-discordant identical twins [5,6]. In their first
paper they studied antigen presentation of influenza by the
dendritic cell subtype, Langerhans cells (LC), and MN using T
cells from the uninfected twin as the readout of antigen
presentation. No defect in the presentation by APC from the
three HIV-infected twins was detected. In the second paper the
authors found no difference in presentation of tetanus by LC from
five HIV-discordant twin pairs. Utilizing a different system, Fidler
et al. used CD4+ T cell clones from uninfected subjects to measure
antigen presentation by MN from HIV-infected individuals. They
found a defect in antigen presentation that varied in magnitude
depending on which T cell clone they tested [7]. These sets of
studies using primary T cells to determine antigen presentation
function demonstrate conflicting results. The basis of our study is
to clarify the issue of antigen processing function in APC from
HIV-infected individuals using a novel and highly sensitive
measurement of MHC-II antigen processing and presentation.
Additionally, we will determine if there is a relationship between
HLA-DR levels and antigen presentation.
HLA-DR restricted CD4+ T cell hybridomas were used to study
MHC-II antigen processing. Hybridomas are stable immortal cell
lines that provide quantitative and reproducible responses ideal for
detailed mechanistic studies [8]. They were generated in HLA-DR
transgenicmice,butrespond tohumanAPCaspreviouslydescribed
[9],andsecrete IL-2 inproportiontotheamountofspecificpeptide-
MHC on the APC surface. Classically T cell hybridomas are
thought to be less costimulation dependent and therefore provide a
readout that is largely dependent on levels of expression of
peptide:MHC-II complexes only. These murine T cells are also
notinfectablebyHIV.T cellhybridomasrespond immediatelyafter
thawing from cryopreservation permitting a single large stock of T
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only variable in the experimental system. We tested the hypothesis
that MN from HIV-infected persons are deficient in MHC-II
antigen processing and presentation.
Methods
Isolation and Storage of PBMC
Recruitment and participation of healthy and HIV-infected
subjects was approved by University Hospitals Case Medical
Center Institutional Review Board and written informed consent
was obtained from all subjects. HIV-infected individuals were
recruited from the HIV clinic at the Case Western Reserve Center
for AIDS Research. HLA-matched healthy adult donors were
identified among personnel at the university and medical center.
Blood was collected in EDTA containing tubes and processed
within 90 minutes of collection (BD Diagnostics). PBMC were
isolated by Ficoll Paque Plus (Amersham Biosciences) density
gradient centrifugation and stored in liquid nitrogen in medium
containing 90% FCS/10% DMSO. HLA-typing was performed
by PCR using kits (Biosynthesis) on DNA isolated from whole
blood. Potential subjects first had low resolution screening to
identify HLA-DR15 and HLA-DR1 status. Their DNA then
underwent high-resolution analysis to confirm that they were
HLA-DR15.01 and HLA-DR1.01 subtype. Only subjects that
were HLA-DR1.01 and HLA-DR15.01 were studied.
Isolation of Monocytes
Untouched MN were isolated from thawed aliquots of PBMC
using the Monocyte Isolation Kit II (Miltenyi Biotec) according to
the manufacture’s instruction with the following modifications.
Anti-CD1c antibody and anti-CD2 beads were added to minimize
contamination by T cells and myeloid dendritic cells. Purity and
HLA-DR expression on MN was determined immediately after
isolation by flow cytometry after staining with anti-CD14-PE, anti-
DR-APC, and isotype control antibodies (BD Biosciences). The
average MN purity after isolation was 70% in HIV-infected and
73% in uninfected individuals with no significant difference
between the two groups (p.0.5).
T Cell Hybridoma Generation
T cell hybridomas were generated using IACUC approved
protocols with a method that is previously described [8,9]. Briefly,
15 HEL T cell hybridoma line was generated by immunizing
HLA-DR15.03 transgenic mice (Chella David, Mayo Clinic) with
Hen Egg Lysozyme (HEL, Roche) in complete Freund’s adjuvant
(Gibco). After 7 days, draining lymph nodes were harvested and
restimulated in vitro for 5 days. Cells were fused with a TCR
deficient line BW1100 [10] with polyethylene glycol (Boehringer
Mannheim). HEL-specific cells were identified by screening for
presentation by a HLA-DR15.01+ EBV transformed B cell line.
The specific HEL-epitope recognized by 15HEL was determined
by testing peptides (Genemed Synthesis, S. San Francisco, CA)
Figure 1. HLA-DR levels on MN from HIV-infected and uninfected individuals. Purified MN were labeled with anti-CD14 to identify the MN
and MFI of HLA-DR. A (upper panel). Representative dot plot of the gating strategy of the single CD14+ population is presented. A (lower panel).
Representative histogram of HLA-DR (grey) and isotype control (dotted black) levels. B. HLA-DR levels of control and HIV infected subjects. Black
circles for viremic individuals (VL.1000), black dash subjects with VL,1000, and red circles uninfected controls.
doi:10.1371/journal.pone.0009491.g001
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algorithms from ProPed (http://www.imtech.res.in/raghava/
propred/) and RANKPEP (http://immunax.dfci.harvard.edu/
Tools/rankpep.html). 1ACD5 T cell hybridoma is an HLA-
DR1.01 restricted clone that recognizes HIV reverse transcriptase
(RT, aa 350–364) as previously described [8,9].
T Cell Assay
For the antigen presentation assays, MN (5610
4/well) and T cell
hybridoma (1610
5/well) were plated in 96-well flat bottom plates in
triplicate with recombinant RT, HEL, or peptides in DMEM based
medium with 10% FCS [11]. After 24h, supernatants were
harvested and IL-2 levels measured by ELISA (eBioscience).
Results
MHC-II Levels on MN from HIV-Infected Individuals
MHC-II HLA-DR is one of the predominant antigen
presentation molecules for CD4+ T cells. HLA-DR levels were
measured on purified MN for all subjects by flow cytometry.
Fig. 1A demonstrates the gating strategy used to measure HLA-
DR on purified CD14+ MN. Mean florescent intensity (MFI) of
HLA-DR was found to be significantly less (Fig. 1B, p,0.03) in
HIV-infected individuals (MFI 281, SD 79) than uninfected
subjects (MFI 352, SD 105). While there was a 20.2% reduction in
HLA-DR on MN from HIV-infected group as a whole, HLA-DR
levels on MN from viremic subjects (VL.1000) were more similar
to those of the control population. We sought to determine the
functional consequences of this HLA-DR reduction by measuring
antigen presentation in these same MN.
Characterization of the T Cell Hybridoma Lines
HLA-DR restricted T cell hybridomas were used to measure
antigen processing and presentation by MN. T cell hybridomas for
use with human APC were characterized in three ways. First was
to confirm that the T cell hybridoma recognizes the appropriate
protein by mapping the exact peptide recognized. The second was
to confirm HLA-DR restriction. Last, the costimulation depen-
dence of the T cell hybridomas was determined.
As published previously, the RT-specific T cell hybridoma
1ACD5 recognized RT aa 350–364, was restricted to HLA-
DR1.01, and did not require CD80/86 costimulation [11]. For the
current study, the peptide specificity of the 15HEL clone was
mapped. Rather than purchase an entire set of overlapping
Figure 2. Characterization of T cell hybridoma clone 15HEL. MN (5610
4/well) were incubated with antigen (intact HEL for A and C, HEL
peptides for B) and 15HEL (1610
5/well) for 24 hrs. Supernatants were harvested, and IL-2 measured by ELISA. A. Effect of anti-HLA-DR or isotype on
response. B. Identification of HEL peptide epitope recognized by 15HEL. C. Effect of anti-CD80 and CD86 antibodies together (5 mg/ml of each) or
isotype control (10 mg/ml) on responses. Results of A and C represent triplicate wells and error bars SEM.
doi:10.1371/journal.pone.0009491.g002
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candidate peptides from HEL that would bind HLA-DR15.01.
This limited set of peptides was synthesized and tested. 15HEL
responded only to HEL aa 14–37 (Fig. 2A). HLA-DR restriction
was confirmed using anti-DR antibodies that significantly
inhibited 15HEL responses (Fig. 2B). 15HEL did not recognize
non-HLA-DR15 expressing APC (data not shown). The addition
of anti-CD80/86 antibodies only minimally diminished IL-2
production by 15HEL demonstrating that 15HEL activation by
MN was not CD80/86 costimulation dependent (Fig. 2C).
Antigen Processing and Presentation by MN from HIV-
Infected Individuals
The goal of these studies was to determine if MN from HIV-
infected individuals have an antigen processing and presentation
defect. Processing and presentation by the HLA-DR1.01+ and
DR15.01+ MN were analyzed separately since two different T
hybridomas were used to measure antigen presentation. Table 1
describes the clinical features of 8 HLA-DR1.01+ and 6 HLA-
DR15.01+ HIV-infected subjects studied. 12 HLA-DR1.01+ and
12 HLA-DR15.01+ uninfected healthy controls served as the
control group for comparison.
Figure 3. Antigen presentation by HLA-DR1+ MN from individual HIV-infected and uninfected subjects. In all four panels, MN (5610
4/
well) were incubated with soluble antigen or peptide and T cell hybridoma (1610
5/well) for 24 hrs. Viremic HIV-infected individuals with VL.1000 are
High VL and VL,1000 are Low VL. A. Control MN and soluble RT, B. HIV+ MN and soluble RT, C. Combined data on soluble RT presentation, D. Control
MN and peptide, E. HIV+ MN and peptide, F. Combined data on peptide presentation.
doi:10.1371/journal.pone.0009491.g003
Table 1.
SUBJECT VLOAD CD4+ ARV
HIV1 ,50 785 Yes
HIV2 57 1476 Yes
HIV3 .100000 56 No
HIV4 ,50 772 Yes
HIV5 4810 685 Yes
HIV6 ,50 576 Yes
HIV7 ,50 1342 Yes
HIV8 21300 228 No
HIV10 ,50 104 Yes
HIV11 10600 28 No
HIV12 794 218 Yes
HIV13 8240 221 No
HIV14 ,50 185 Yes
HIV16 99400 426 No
doi:10.1371/journal.pone.0009491.t001
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concentrations of soluble antigen and peptide. Soluble antigen
must be taken up, processed, and presented while peptide can be
exchanged on the MN surface and does not require intracellular
processing to be presented. Fig. 3 and 4 demonstrate presentation
of soluble antigen and peptide by MN from HIV-infected and
uninfected control donors of HLA-DR1 (Fig. 3) and HLA-DR15
types (Fig. 4). Responses by the uninfected-controls and HIV-
infected individuals for each HLA-DR type were compared as a
group (Fig. 3C, 3F, 4C, 4F). There was no statistical difference
between antigen presentation from HIV-infected and uninfected
groups at every soluble antigen or peptide concentration tested
(p.0.1).
The study did not have the power to examine the effects
specifically of viremia or use of ARV on antigen presentation. The
individual viremic subjects were indicated on the figure of raw
data of all the subjects (Fig. 3 and 4). One viremic donor (HIV 5)
on self-report said that he was taking ARV while all the other
viremic individuals did not report current ARV use. Based on the
presentation by the individual subjects in Fig. 3 and 4, there does
not appear to be a clear trend that viremia or use of ARV results in
loss of antigen presentation ability compared to uninfected
controls. In addition, there was no relationship between antigen
presentation and CD4+ T cell level (data not shown).
Since HLA-DR levels were measured on MN for all subjects by
flow cytometry, the relationship between HLA-DR level and
antigen presentation was determined. In order to increase the
power for the analysis, all data from the HLA-DR1 and DR15+
subjects were included (n=38). Data were normalized to allow this
by dividing the mean level of IL-2 produced by the control group
in their respective HLA-DR types by the IL-2 value for that same
antigen or peptide in each individual subject. Analysis of the
middle concentration of antigen and peptide was chosen to
determine this correlation because virtually all of the subjects had
IL-2 values at this concentration of antigen or peptide that were
above the limit of detection of the IL-2 ELISA assay but also not at
plateau of the response. The ratio of presentation was then
analyzed using Spearman’s rank correlation. There was a small
but significant correlation of antigen presentation of the soluble
antigens and HLA-DR (Fig. 5A, r=0.32, p=0.049) and peptide
presentation and HLA-DR (Fig. 5B, r=0.38, p=0.02). Interest-
ingly, the 20.2% reduction in HLA-DR expression in the HIV-
infected individuals (Fig. 1) was not reflected in a drop in antigen
presentation however (Fig. 3 and 4).
Figure 4. Antigen presentation by HLA-DR15+ MN from individual HIV-infected and uninfected subjects. MN (5610
4/well) were
incubated with soluble HEL or peptide and T cell hybridoma (1610
5/well) for 24 hrs. Viremic HIV-infected individuals with VL.1000 are High VL and
VL,1000 are Low VL. A. Control MN and soluble HEL, B. HIV+ MN and soluble HEL, C. Combined data on soluble HEL presentation, D. Control MN and
peptide, E. HIV+ MN and peptide, F. Combined data on peptide presentation.
doi:10.1371/journal.pone.0009491.g004
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APC dysfunction could be a significant factor in immune
dysfunction since both cell mediated and humoral immunity rely
on APC function to activate their specific responses. There have
been several in vitro studies where macrophages are infected with
HIV or transfected to express specific HIV molecules such as Nef
and Vpu [2,12,13,14]. These studies have demonstrated multiple
inhibitory effects on APC function by HIV virions or specific HIV
products. These effects include inhibition of MHC-II expression,
increase in invariant chain expression, decrease in antigen uptake,
and decreased antigen presentation overall. These studies though
all have a similar feature in their experimental systems of very high
levels of HIV-infection or expression of a transfected HIV
molecule. This is not the case in vivo where the frequency of
HIV-infected MN and macrophages is very low. In addition it is
well known that MN are resistant to becoming productively
infected due to a pre-integration block [15]. Both of these features
suggest that APC dysfunction if present would be due to bystander
effects rather than direct infection. We did not detect a defect in
either antigen processing or presentation by MN isolated from
HIV+ individuals. Our results using a very specific measurement
tool of MHC-II antigen processing and presentation are similar to
the observations reported by Blauvelt et al. [5,6].
Several older studies have examined antigen presentation
function by APC from HIV-infected individuals using primary
human CD4+ T cells. These data must be interpreted with caution
because of several confounding factors. HIV infection of the human
CD4+ T cell lines is a major potential confounder. Release of
modulatory cytokines by APC from HIV-infected individuals
affecting T cell responses is also possible. We attempt to minimize
these uncontrolled effects through our HLA-DR transgenic murine
T cell hybridoma system. These murine T cell lines cannot be
infected by HIV and some cytokine or chemokine effects if present
might not signal across the xeno barrier. T cell hybridomas are
relatively costimulation independent permitting specific measure-
ment of specific peptide-loaded MHC-complexes. All of these
features make use of DR-restricted T cell hybridomas an excellent
means to measure the generation and presentation of peptide:MHC
complexes in isolation from effects on human CD4+ T cells.
Our study demonstrates that antigen processing and presenta-
tion of soluble antigen is preserved in MN from HIV-infected
individuals. It is difficult to screen and match the HLA-DR type
and subtype to have a large number of subjects. It is possible that
there are small antigen presentation defects in specific subgroups
of individuals that would be detectable with a larger sample size.
The current dataset did not establish a relationship between HIV
viral load, CD4 count, and antigen presentation.
In the literature there are varying reports from an increased
level of HLA-DR on APC from HIV-infected individuals to
somewhat diminished levels [5,16,17,18,19,20,21]. It is not clear
why MN from HIV-infected individuals have 20% lower HLA-
DR but their antigen presentation is not similarly diminished in
our study. It is possible that the magnitude of HLA-DR reduction
is not great enough to have a measurable effect on antigen
presentation with our sample size. However, in previous data
examining antigen presentation by cord blood MN [11], we did
not find a correlation between antigen presentation and HLA-DR
levels. In the current study we found only a small correlation
between HLA-DR level and antigen presentation. These data
together suggest that intracellular events are the most important
determinants of successful antigen processing and presentation and
not merely surface MHC-II levels.
In conclusion, our data using the antigen presentation focused T
cell hybridoma bioassay system suggests that MN from HIV-
infected individuals have preserved MHC-II antigen processing
and presentation function.
Figure 5. Relationship between HLA-DR level and antigen presentation. Data from all 38 subjects in the study were normalized. The
individual’s ratio of presentation was calculated by dividing their IL-2 level for the middle concentration of RT, HEL or peptide by the mean IL-2 level
from the control subjects at the same middle concentration of antigen or peptide. Open red diamonds are data from HIV-infected individuals and
closed black diamonds for uninfected controls.
doi:10.1371/journal.pone.0009491.g005
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